Open AccessThe modern treatment of cardiovascular diseases with b-blockers - focus on the nebivolol.
Author(s) -
А. Г. Евдокимова,
Valeriy Aleksandrovich Ol'khin,
В В Евдокимов,
Ekaterina Viktorovna Zolotareva,
А. Б. Хадзегова
Publication year - 2009
Publication title -
sistemnye gipertenzii
Language(s) - English
Resource type - Journals
eISSN - 2542-2189
pISSN - 2075-082X
DOI - 10.26442/sg33077
Subject(s) - nebivolol , nitric oxide , medicine , cardiology , pharmacology , blood pressure
Unlike first-line antihypertensives, nebivolol, a cardioselective b-blocker with vasodilatatory properties caused by its ability to modulate the activity of nitric oxide, positively affects prognosis in patients with arterial hypertension and chronic heart failure and shows metabolic neutrality. The clinical and pathogenetic studies demonstrating the benefits of nebivolol are discussed.Keywords: nebivolol, arterial hypertension, b-blockers.